HiberCell is a pioneering biotech company based in Saint Paul, MN, dedicated to revolutionizing cancer treatment. They focus on developing differentiated therapeutic approaches that target adaptive stress induction in tumors, aiming to overcome treatment resistance, relapse, and metastasis. With a mission to enable patients to live longer, cancer-free lives, HiberCell is working to exploit stress-driven vulnerabilities in cancer cells through innovative treatment strategies.
Their clinical-stage therapeutic candidates include HC-7366, designed to activate the GCN2 kinase and disrupt the Integrated Stress Response signaling pathway, HC-5404, which inhibits the PERK kinase and targets the Unfolded Protein Response pathway, and Odetiglucan, a systemically administered candidate that modulates tumor-immune interactions to induce a strong anti-cancer immune response. Led by a proven leadership team, HiberCell combines traditional drug development methods with computational expertise to efficiently advance their first-in-human therapeutics, driven by scientific rigor and urgency.
Generated from the website